Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 1
2020 3
2021 3
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Machine learning survival models trained on clinical data to identify high risk patients with hormone responsive HER2 negative breast cancer.
Fanizzi A, Pomarico D, Rizzo A, Bove S, Comes MC, Didonna V, Giotta F, La Forgia D, Latorre A, Pastena MI, Petruzzellis N, Rinaldi L, Tamborra P, Zito A, Lorusso V, Massafra R. Fanizzi A, et al. Among authors: pastena mi. Sci Rep. 2023 May 26;13(1):8575. doi: 10.1038/s41598-023-35344-9. Sci Rep. 2023. PMID: 37237020 Free PMC article.
Analyzing breast cancer invasive disease event classification through explainable artificial intelligence.
Massafra R, Fanizzi A, Amoroso N, Bove S, Comes MC, Pomarico D, Didonna V, Diotaiuti S, Galati L, Giotta F, La Forgia D, Latorre A, Lombardi A, Nardone A, Pastena MI, Ressa CM, Rinaldi L, Tamborra P, Zito A, Paradiso AV, Bellotti R, Lorusso V. Massafra R, et al. Among authors: pastena mi. Front Med (Lausanne). 2023 Feb 2;10:1116354. doi: 10.3389/fmed.2023.1116354. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36817766 Free PMC article.
Robustness Evaluation of a Deep Learning Model on Sagittal and Axial Breast DCE-MRIs to Predict Pathological Complete Response to Neoadjuvant Chemotherapy.
Massafra R, Comes MC, Bove S, Didonna V, Gatta G, Giotta F, Fanizzi A, La Forgia D, Latorre A, Pastena MI, Pomarico D, Rinaldi L, Tamborra P, Zito A, Lorusso V, Paradiso AV. Massafra R, et al. Among authors: pastena mi. J Pers Med. 2022 Jun 10;12(6):953. doi: 10.3390/jpm12060953. J Pers Med. 2022. PMID: 35743737 Free PMC article.
A ultrasound-based radiomic approach to predict the nodal status in clinically negative breast cancer patients.
Bove S, Comes MC, Lorusso V, Cristofaro C, Didonna V, Gatta G, Giotta F, La Forgia D, Latorre A, Pastena MI, Petruzzellis N, Pomarico D, Rinaldi L, Tamborra P, Zito A, Fanizzi A, Massafra R. Bove S, et al. Among authors: pastena mi. Sci Rep. 2022 May 12;12(1):7914. doi: 10.1038/s41598-022-11876-4. Sci Rep. 2022. PMID: 35552476 Free PMC article.
Biomarker phenotyping drives clinical management in axillary sentinel node: A retrospective study on women with primary breast cancer in 2002.
Diotaiuti S, De Summa S, Altieri R, Dantona C, Tommasi S, Di Gennaro M, Rubini G, Pastena MI, Argentiero A, Zito FA, Silvestris N, Paradiso AV. Diotaiuti S, et al. Among authors: pastena mi. Oncol Lett. 2020 Sep;20(3):2469-2476. doi: 10.3892/ol.2020.11793. Epub 2020 Jul 1. Oncol Lett. 2020. PMID: 32782565 Free PMC article.
11 results